Previous Article | Next Article 
Molecular and Cellular Biology, October 2000, p. 7363-7377, Vol. 20, No. 19
0270-7306/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
c-Src Signaling Induced by the Adapters Sin and Cas
Is Mediated by Rap1 GTPase
Luzhou
Xing,1
Chang
Ge,1
Ross
Zeltser,1
Gregory
Maskevitch,1
Bruce J.
Mayer,2 and
Konstantina
Alexandropoulos1,*
Department of Pharmacology, College of
Physicians and Surgeons of Columbia University, New York, New York
10032,1 and The Children's Hospital,
Boston, Massachusetts 021152
Received 24 March 2000/Returned for modification 24 May
2000/Accepted 29 June 2000
 |
ABSTRACT |
Oncogenic Src proteins have been extensively studied to gain
insight into the signaling mechanisms of Src. To better understand signaling through wild-type Src, we used an approach that involves activation of Src signaling through the binding of physiologic ligands
to the Src SH3 domain. To this end, we used full-length and truncated
versions of the multiadapter molecules Cas and Sin to activate c-Src,
and we examined the intracellular pathways that mediate Src signaling
under these conditions. We show that although all proteins bind to and
are phosphorylated by c-Src, quantitative differences exist in the
ability of the different ligands to activate c-Src signaling. In
addition, we show that Sin- and Cas-induced Src signaling, as assayed
by transcriptional activation, is exclusively mediated through a
pathway that involves the adapter Crk and the GTP-binding protein Rap1.
These data are in contrast to previous observations showing Ras to
mediate signaling downstream of transforming Src alleles. In our
system, we found that signaling through the oncogenic SrcY527 mutant is
indeed mediated by Ras. In addition, we found that Rap1 also mediates oncogenic Src signaling. Our results show for the first time that Rap1
mediates c-Src kinase signaling and reveal mechanistic differences in
the signaling properties of wild-type and transforming Src proteins.
 |
INTRODUCTION |
The nonreceptor protein tyrosine
kinase Src is critical for normal cellular processes such as
proliferation and differentiation, and certain mutations in Src cause
uncontrolled cell proliferation and transformation (11).
Under normal conditions, the enzymatic activity of Src is tightly
regulated. Biochemical (13, 20, 45, 64) and structural
(75, 92) analyses have shown that the kinase activity of the
c-Src protein is intramolecularly regulated by conserved modular
domains, the Src homology regions 2 and 3 (SH2 and SH3)
(18). Consistent with their regulatory role, mutations within these domains render the kinase active and oncogenic
(11). In addition, upon Src activation, these domains
mediate protein-protein interactions and are thought to determine
substrate selectivity and signaling specificity (18, 28).
Traditionally, studies aimed at elucidating the signaling properties of
c-Src have used constitutively active and transforming Src alleles as
models. Activated Src alleles exhibit deregulated kinase activity and
are known to induce multiple signaling responses due to promiscuous
substrate phosphorylation. Thus, it has been difficult to determine
which of the many responses is responsible for the signaling properties
of Src. In addition, despite the identification of a plethora of
putative Src substrates in v-Src-transformed cells, the importance of
these substrates in the physiologic and/or tumorigenic effects of c-Src
has been difficult to ascertain.
To gain insight into the signaling mechanisms of wild-type c-Src and
given that the c-Src SH3 domain has been shown to participate in the
intramolecular negative inhibition of the c-Src kinase activity
(55, 79), we used physiological ligands for the conserved SH3 domain of c-Src to activate the enzyme. At the same time, we used
these ligands as links to downstream events to study the signaling
mechanisms and specificity of c-Src. The molecules used for our studies
consist of a protein that we previously identified, Sin, and the
homologous protein p130Cas (1, 72). Cas was
first identified as a highly phosphorylated protein in v-Src- and
v-Crk-transformed cells (72); Sin was independently cloned
as the Fyn embryonic substrate Efs (40). These molecules
specifically bind to Src family SH3 domains with high affinity through
proline-rich motifs (2, 57, 72). Sin and Cas comprise a
multiadapter protein family that also includes HEF1/CasL independently
cloned as a human enhancer of filamentation in yeast and as a focal
adhesion kinase (FAK)-binding protein expressed in lymphocytes
(48). All of these proteins exhibit conserved secondary
structures, which in turn consist of many conserved modules that
mediate protein-protein interactions. Thus, Cas proteins have conserved
N-terminal SH3 domains, central regions comprised of repeated
tyrosine-containing residues, Src SH3-binding proline-rich motifs
(except HEF1/CasL), and conserved C termini that have been implicated
in homo- or heterodimerization between family members (61).
The presence of these conserved domains and their ability to promote
protein-protein interactions suggest that members of the Cas family
mediate the formation of multiprotein complexes in a
phosphotyrosine-dependent manner. These protein-protein interactions
are thought to subsequently activate intracellular signaling pathways
with pleiotropic effects on cellular behavior (52, 61).
The most extensively studied member of this family,
p130Cas, becomes highly phosphorylated on multiple tyrosine
residues in response to a variety of stimuli. For example, mitogens
such as epidermal growth factor, platelet-derived growth factor, and
lysophosphatidic acid have been shown to induce tyrosine
phosphorylation of Cas (15, 59). In addition, integrin
engagement or stimulation of serpentine receptors such as the bombesin
and the endothelin receptors stimulate Cas phosphorylation (15,
47, 87, 88). Cas phosphorylation in turn has been implicated in
multiple cellular processes such as integrin receptor signaling
(36, 50, 58, 88), cell migration and survival (14, 16,
17, 44), regulation of the cell cycle (60, 93), and
apoptosis (7). Furthermore, Cas has been implicated in
cellular transformation, as demonstrated by its presence as a
tyrosine-phosphorylated protein in v-Src- and v-Crk-transformed cells
(72), by the fact that p130Cas
/
cells cannot
be transformed by Src (37), and by antisense RNA experiments
showing that Cas-specific antisense RNA partially reverts v-Src
transformation (6).
Multiadapter molecules, such as the Cas protein, depending on the type
and number of conserved motifs they contain, can form interactions with
unique sets of cytoplasmic intermediates and thus determine signaling
specificity. These conserved motifs have tyrosine-containing sequences
(Y motifs) which upon phosphorylation by tyrosine kinases recruit
cytoplasmic substrates through phosphotyrosine-SH2 domain interactions.
The type and number of Y motifs present on the different members of the
Cas family differ, suggesting that these proteins may have similar but
not identical functions. Consistent with the model that Y motifs can
determine signaling specificity, the multiadapters and insulin receptor
substrates IRS1 and -2 (56, 94) have been shown to mediate
distinct functions of the insulin receptor (5, 80, 89). The
different signaling properties of each molecule have been attributed to
unique Y motifs that bind to distinct SH2 domain-containing cytoplasmic intermediates.
We have previously shown that coexpression of Src and Sin activates Src
signaling, as measured by serum response element (SRE)-mediated transcriptional activation (1). In this study we compared
the abilities of the Src SH3-binding proteins Cas and Sin to bind to
and stimulate the enzymatic activity of c-Src. We then analyzed the
molecular events that mediate Sin-Cas-induced Src signaling, using the
phosphorylated forms of these proteins as links to downstream signaling
events. In addition, we compared the signaling mechanisms of
ligand-activated c-Src to signaling mediated by a constitutively active
and oncogenic Src mutant. In these experiments, we used full-length and
truncated forms of Sin and Cas proteins, and we found quantitative
differences in the ability of the different Sin and Cas proteins to
activate c-Src signaling. In addition, we found that ligand-activated
and constitutively active Src proteins utilize different signaling
mechanisms to induce SRE-dependent transcription.
 |
MATERIALS AND METHODS |
Cells and antibodies.
Human embryonic kidney carcinoma 293 cells were grown as previously described (62). Cells were
maintained in Dulbecco modified Eagle medium containing 10% fetal
bovine serum, penicillin (100 U/ml), and streptomycin (100 mg/ml). The
Sin monoclonal antibody, raised against a fragment of Sin encompassing
amino acids 142 to 258, was generated by Transduction Laboratories. Cas
polyclonal antibody CasN-17 was purchased from Santa Cruz
Biotechnology. The Src mouse monoclonal antibody 327 was provided by
Joan Brugge (Harvard Medical School); the antiphosphotyrosine
monoclonal antibody pY20 was purchased from Transduction Laboratories.
Antiphosphotyrosine SrcY416 was kindly provided by A. Laudano
(University of New Hampshire). Other reagents used were
anti-phospho-ERK monoclonal antibody (E-4), anti-ERK, anti-C3G (Santa
Cruz), anti-Ras, anti-Rap1, anti-Crk (Transduction Laboratories), and
anti-hemagglutinin epitope (HA) (BAbCo, Richmond, Calif.).
DNA constructs.
DNA manipulations were performed by standard
protocols. Full-length Sin and truncated Sin
C (amino acids 1 to 335)
were cloned into the SpeI-NotI sites of the pEBB
expression vector. pEBB was derived from the pEF-BOS expression vector
driven by the human elongation factor 1-
promoter (53).
In Sin
C, a deletion of amino acids 340 to 560 removes one of the
proline-rich Src SH3-binding sites, the last three Y motifs in the
substrate region, and the C-terminal homologous region. PCR-amplified
Cas proteins were cloned into the BamHI-NotI
sites of pEBB. Full-length Cas expresses a short form of the protein
that is alternatively spliced, missing amino acids 5 to 99 (72). Cas
UR contains an internal deletion of a
Bsu36I fragment encompassing amino acids 496 to 713 that removes the unique region of Cas. Cas
UR
C contains, in addition to
the Bsu36I fragment deletion, a C-terminal deletion that
encompasses amino acids 748 to 968. This construct was generated by PCR
amplification using Cas
UR as a template and synthetic
oligonucleotides containing 5' BamHI and 3' NotI
restriction sites. Cas
UR
CP* was generated as the Cas
UR
C
construct except that the 3' oligonucleotide that was used for PCR
amplification contained two base pair substitutions that produce two
point mutations (Ser-Ala and Pro-Leu) in the sequence within the core
of the PXXP motif of Cas. These substitutions change the Src
SH3-binding site of Cas for that of Sin (PSPP to PALP). All sequences
were confirmed by automated sequence analysis. The different Sin
C
YDVP mutants were generated by PCR by substituting tyrosines 148, 188, and 253 with phenylalanine residues, using mutated oligonucleotides.
The amplified fragments were cloned into the
SpeI-NotI sites of pEBB, and mutations were
confirmed by automated sequencing. Plasmids expressing the RasN17 and
CrkW170K mutants were previously described (30, 81). The
RapN17 mutant was provided by Philip Stork (Oregon Health Sciences
University) (86). The SRE-luciferase reporter construct was
generated as previously described (1); the AP-1 luciferase
reporter was provided by C. A. Hauser (La Jolla Cancer Research
Foundation). Plasmids that expressed wild-type Src protein and SrcY527F
have been described elsewhere (45), as has the v-Raf
construct (68).
Transfections.
293 cells were transfected as previously
described (1, 62). Two micrograms of pMHHB(c-Src) or
pc-SrcY527F expression vector or pEVX empty vector was used in all
transfections. The transfection mixtures also included 1 µg of vector
(pEBB) used to express the different Sin or Cas proteins or 1 µg of
Sin- and Cas-expressing pEBB and different concentrations of the
inhibitors as shown in the figures. SRE and AP-1 luciferase reporters
and the MFG-lacZ plasmid expressing
-galactosidase (1 µg of each) were also included in the transfection mixtures. When
necessary, the total amount of DNA in each transfection mixture was
kept constant by the addition of empty vector in the DNA-calcium
phosphate coprecipitate. Luciferase activity was determined using a
Promega kit according to the manufacturer's protocol;
-galactosidase activity to normalize for transfection efficiency
between the different samples was determined according to standard
protocols (73).
Immunoprecipitations.
Immunoprecipitations were performed as
previously described (1). Briefly, cells were lysed in 1 ml
of ice-cold NP-40 lysis buffer (1% NP-40, 20 mM Tris-HCl [pH 8.0],
150 mM NaCl, 10% glycerol, 10 mM NaF, 1 mM sodium orthovanadate, 1 mM
phenylmethylsulfonyl fluoride, 10 µg of aprotinin/ml, 10 µg of
leupeptin/ml) and incubated on ice for 10 min. The cell debris and
nuclei were removed by centrifugation in an Eppendorf centrifuge for 10 min at 4°C. The cell lysates were then incubated with the specified
antibodies at concentrations suggested by the manufacturers for 2 h at 4°C. The immune complexes were collected after the addition of
20 µl of protein G-plus-protein A-agarose (Oncogene Science) and
incubation at 4°C for 30 min. The pellets of agarose beads were
washed three times with 1 ml of lysis buffer and then subjected to
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
and immunoblotting.
Western blot analysis.
Total cell extracts or
immunoprecipitates normalized for protein content were boiled in
Laemmli sample buffer, separated by SDS-PAGE on a 10% gel, and
transferred to nitrocellulose membranes. Filters were blotted with the
appropriate monoclonal antisera according to manufacturer's protocol
in TBST-milk at 4°C overnight (16 h). Rabbit polyclonal antibodies
were used at 1:500 dilution. Monoclonal antibodies were each used at 1 µg/ml of TBST-milk. The filters were washed in TBST and consequently
incubated with anti-mouse or anti-rabbit immunoglobulin G-conjugated
horseradish peroxidase at a 1:4,000 dilution in TBST at room
temperature for 1 h. Filters were then washed and developed by
enhanced chemiluminescence (ECL) (Amersham) as described by the manufacturer.
Ras and Rap1 binding assays.
Transfected 293 cells were
lysed with cold lysis buffer (50 mM Tris [pH 7.5], 1% Triton X-100,
1 mM EDTA, 1 mM EGTA, 0.1% 2-mercaptoethanol, 0.5 mM sodium
orthovanadate, 50 mM NaF, 5 mM sodium pyrophosphate, 10 mM sodium
glycerophosphate, 0.1 mM phenylmethylsulfonyl fluoride), and aliquots
of the cell extracts containing 50 µg of total protein were mixed
with 40 µl crude bacterial extracts expressing glutathione
S-transferase (GST)-RalGDS-RBD (Rap1-binding domain) or
Raf1-RBD (Ras-binding domain) that had been precoupled to glutathione
beads in the presence of 125 mM NaCl. The aliquots were incubated
1 h at 4°C with rotation. The protein complexes were washed,
separated by SDS-PAGE on a 15% polyacrylamide gel, transferred on
nitrocellulose membranes, and blotted with Ras- and Rap1-specific antibodies.
 |
RESULTS |
Differential activation of Src signaling by Sin and Cas.
To
gain insight into the specificity of c-Src signaling, we compared the
abilities of wild-type and mutated forms of Sin and Cas proteins to
bind to and activate Src. Although the Sin and Cas proteins do not
share extensive primary sequence homology, they are closely related in
their overall secondary structure (Fig.
1). For example, they both contain
proline-rich consensus motifs that exhibit high binding affinity to the
Src SH3 domain (1, 72) and are important for Src binding.
The proline-rich motif of Cas has been shown to mediate association of
this protein with Src and is important for Src-dependent
phosphorylation of Cas (57). A point mutation within the
proline-rich motif of a truncated fragment of Sin or deletion of the
Sin proline-rich consensus leads to inhibition of Src signaling
(reference 1 and unpublished observations). The
N-terminal SH3 domains and the C termini of Cas and Sin are conserved
(90 and 57%, respectively), and their central regions contain multiple
tyrosine motifs that mediate substrate binding through
phosphotyrosine-SH2 domain interactions. In addition, Cas contains a
unique region of unknown function between its substrate-binding region
and its C terminus. Given the homology of these proteins, we compared
the abilities of Sin and Cas to bind to and activate c-Src, as well as
their abilities to become phosphorylated and promote Src-dependent
intracellular signaling.

View larger version (25K):
[in this window]
[in a new window]
|
FIG. 1.
Schematic representation of full-length and truncated
Sin and Cas proteins and comparison of their Y motifs. The constructs
were generated as described in Materials and Methods. SR,
substrate-binding regions of Sin and Cas that contain the motifs shown
on the right; P, proline-rich sequences that bind to the Src SH3,
RPLPALP, and RPLPPPP for Sin and RPLPSPP for Cas. Y motifs that are
deleted in truncated Sin and Cas proteins are boxed. Cas UR CP* is
the same as Cas UR C except that the PSPP motif has been changed to
PALP.
|
|
To this end, we generated full-length and truncated versions of the two
proteins as shown in Fig. 1. The conserved C termini of both Sin and
Cas were deleted, given that they negatively regulate the signaling
properties of the proteins (see below), as well as the unique region of
Cas to more closely approximate the overall structure of Sin.
Furthermore, the proline-rich, Src SH3-binding site of Cas was
exchanged for that of Sin, to test whether the affinities of these
sites for the Src SH3 were functionally equivalent (Fig. 1). Finally,
HA-tagged forms of truncated Cas and Sin proteins were generated and
compared to unmodified full-length and truncated Cas and Sin proteins.
Immunoprecipitation assays revealed that the Sin and Cas proteins
associated with c-Src when coexpressed in 293 cells and were
phosphorylated on tyrosine residues (Fig. 2A, top panel, lanes 2 to 9). The
phosphorylation of the Sin and Cas proteins depended on c-Src
coexpression, since only minor or undetectable phosphorylation of these
proteins was observed in the absence of Src (pEVX vector) and in the
presence of a Src kinase mutant (c-SrcK295R) (Fig. 2A, middle and
bottom panels, respectively). These results suggest that these Sin and
Cas proteins associate with Src and become phosphorylated in vivo in a
Src-dependent manner.

View larger version (50K):
[in this window]
[in a new window]
|
FIG. 2.
Sin and Cas associate with and are phosphorylated by
c-Src. (A) 293 cells were cotransfected with a full-length or truncated
Sin or Cas expression vector (1 µg of each) and a c-Src expression
plasmid, the pEVX empty vector used to express Src, or the c-SrcK295R
kinase mutant (2 µg of each). Cell lysates were subjected to
immunoprecipitation (IP) using anti-Src antiserum, and Western blots of
the immunoprecipitates were blotted with pY20, an antibody against
phosphotyrosine. In lane 1, cells were transfected with pEBB vector
backbone used to express Sin and Cas proteins; lanes 2 to 9 contain the
different Sin and Cas proteins as shown at the bottom. (B) 293 cells
were transfected with Src and Sin or Cas expression constructs as in
panel A. Untransfected controls (U) were included to compare the levels
of endogenous versus overexpressed Src. Cell lysates were
immunoprecipitated with Src antibody; immune complexes were separated
by SDS-PAGE, transferred to nitrocellulose, and blotted with antibody
pY416, which recognizes the active form of Src (top panel). The blots
were stripped and reprobed with anti-Src antibody to determine the
relative levels of Src in the different lanes (lower panel). (C) The
top panel represents total lysates from cells transfected with 1 µg
each of the Sin and Cas proteins on a Western blot probed with Sin-,
Cas-, or HA-specific antibodies. The bottom panel contains the same
extracts blotted with the CasN-17 antibody. Protein bands on the
different blots were visualized using horseradish peroxidase-conjugated
secondary antibody and ECL reagents. All blots were exposed on film for
the same amount of time (10 s).
|
|
To address whether association of Sin or Cas with Src directly
stimulated the enzymatic activity of Src, we generated lysates from 293 cells coexpressing Src and Sin or Src and Cas proteins. Cell extracts
were immunoprecipitated with anti-Src-specific antibody and blotted
with a polyclonal antiserum that specifically recognized the
phosphorylated form of tyrosine 416 of c-Src but not the
nonphosphorylated form or other phosphorylated tyrosines (1,
54). Tyrosine 416 is located within the activation loop of the
Src kinase domain (92), and its phosphorylation correlates
with increased Src activity (45). We found that all of the
Cas and Sin proteins that we used were able to induce Y416
phosphorylation to various degrees (Fig. 2B, upper panel, lanes 2 to 9)
compared to untransfected control cells or cells transfected with the
vector backbone used to express Sin and Cas (pEBB; lane 1). Full-length
Cas and a Cas mutant missing only the unique region of the protein
(Cas
UR) were less able to induce Y416 phosphorylation when
coexpressed with c-Src (Fig. 2B, upper panel, lanes 4 and 5),
suggesting that the different proteins, although phosphorylated,
differentially induce Src activation. The total amounts of Src were
similar in the different samples (Fig. 2B, lower panel), showing that
the effects on Y416 phosphorylation were specific and not due to
differences in c-Src levels. These data suggest that both Sin and Cas
can stimulate the enzymatic activity of Src but that some proteins may
be more potent than others in promoting this activation.
Cas and Sin protein expression was confirmed using Sin-, Cas-, and HA
epitope-specific antisera (Fig. 2C, upper panel). However, since we
used different antisera which may exhibit different affinities for
their cognate antigens, we could not directly compare the relative
expression levels of the different proteins. To achieve this goal, we
used a polyclonal antiserum, CasN-17, which recognizes amino acid
residues 105 to 118 of the SH3 domain of Cas and cross-reacts with the
Sin SH3 domain. This cross-reactivity was not unexpected because the
sequence of the Cas peptide used to generate this antiserum is nearly
identical to the corresponding sequence of Sin. Using this antibody, we
determined that the different Sin and Cas proteins were expressed in
similar amounts (Fig. 2C, lower panel).
We next examined whether Sin and Cas could elicit a signaling response
as a result of their association with c-Src as measured by
transcriptional activation. We used reporter constructs that drive the
expression of luciferase from the SRE of the egr-1 gene, a
c-fos-like early-response gene (1, 84), or the
AP-1-binding site of c-jun (33). The activation
of transcription from the SRE promoter is mediated through the
Raf/MEK1,2/ERK and serum response factor (SRF) pathways, while
AP-1-dependent transcription is mediated by the MEKK/c-Jun N-terminal
kinase (JNK) kinase/JNK pathway, as well as in response to increased
Fos expression (12, 51). We found that SRE- and
AP-1-dependent transcription was activated 7- and 12-fold,
respectively, when c-Src and full-length Sin were coexpressed (Fig. 3A
and B, top, lanes 2), whereas full-length Cas had no effect (Fig. 3A and B, lanes 4). On the other hand, Sin
C
(Fig. 1A) greatly stimulated Src-dependent activation of both promoters
(about 33- and 34-fold [Fig. 3A and B, lanes 3]). Other Sin
constructs that contained all the Y motifs as well as the second Src
SH3-binding site, but lacked the conserved C terminus, behaved
similarly to Sin
C (data not shown), consistent with a negative
regulatory role for the C terminus of Sin.

View larger version (31K):
[in this window]
[in a new window]
|
FIG. 3.
The Sin and Cas proteins mediate differential activation
of Src signaling. 293 cells were cotransfected as in Fig. 2 with a Sin
or Cas expression construct (as shown, lanes 2 to 9) and wild-type
c-Src (A and B, top) or the Src kinase mutant (A and B, bottom); 1 µg
of luciferase reporter construct containing the SRE (left) or AP-1
(right) promoter was included in the transfection mix, along with
-galactosidase expression plasmid (1 µg). Luciferase activity was
measured as described in Materials and Methods. The results represent
the average of at least five experiments and are expressed as fold
activation relative to the values obtained with the vector backbone
(pEBB) that was used to express Sin and Cas proteins and was given a
value of 1. The results shown represent the mean ± standard
deviation.
|
|
In parallel experiments, we also tested Cas deletion mutants (Fig. 1A)
for the ability to activate Src. We found that deletion of the internal
unique domain of Cas (Cas
UR), like the full-length protein, had
little effect on the ability of this protein to activate transcription
(Fig. 3A and B, lanes 5). The lack of an effect on transcriptional
activation by Cas and Cas
UR correlated with little or no effect on
Y416 phosphorylation and therefore Src activation (Fig. 2B, lanes 4 and
5), despite the fact that these proteins associated with and were
phosphorylated by Src (Fig. 2A, lanes 4 and 5).
Introduction of an additional deletion that removed the C terminus of
Cas (Cas
UR
C) resulted in a protein that induced transcription of
both SRE and AP-1 promoters to levels similar to that of full-length Sin (10-fold [Fig. 3A and B, lanes 6]). This suggests that, as for
Sin, the conserved C terminus of Cas is involved in the negative regulation of the molecule. However, although this protein grossly resembled Sin
C and activated Src to the same extent as Sin
C (Fig.
2B, lanes 3 and 6), it was less potent than Sin
C in inducing transcription. To exclude the possibility that this effect was due to
the lower affinity of the Cas proline-rich motif for the Src SH3, we
exchanged the proline motif of Cas for that of Sin (Cas
UR
CP*
[Fig. 1A]). This substitution had no greater effect on Src-dependent
transcriptional activation than unmodified Cas
UR
C, suggesting
that the Sin and Cas proline-rich motifs exhibit similar affinities for
the Src SH3 domain (Fig. 3A and B, lanes 7). As with phosphorylation of
the different Sin and Cas proteins, we found that the effect of these
proteins on transcriptional activation was dependent on c-Src, since no
induction of the SRE- and AP-1-luciferase reporters was observed in
the presence of the SrcK295R kinase mutant (Fig. 3A and B, bottom).
Our data showing that deletion of the C termini of Sin and Cas leads to
increased Src activation (Fig. 2A and B) suggest that Sin and Cas may
themselves be regulated through intra- or intermolecular interactions.
Consistent with this observation, addition of GST or an HA tag to
either the N or C terminus of Sin gives rise to a full-length Sin
protein that activates Src to levels similar to those observed with the
truncated Sin protein (reference 1 and unpublished
observations). Thus, to examine functional differences between
full-length and truncated Sin and Cas proteins, structural modifications as a result of epitope tagging were avoided. However, since the truncated Sin and Cas proteins are already deregulated, we
generated HA-tagged Sin
C and Cas
UR
C and tested their ability to bind to and activate Src signaling. We found that although the two
molecules were expressed at similar levels (Fig. 2C, upper panel, lanes
8 and 9) and associated with Src to similar extents (Fig. 2A, upper
panel, lanes 8 and 9), Cas
UR
C was still less potent than Sin
C
in activating SRE-dependent transcription (Fig. 3A, lanes 8 and 9).
Increases in the concentration of transfected plasmid DNA expressing
different Cas proteins had no additional effect on their ability to
induce Src signaling (data not shown). Thus, these results show that
although all of the proteins we used associate with and are
phosphorylated by Src, they differ quantitatively in the ability to
activate Src and mediate Src signaling.
Sin and Cas-induced Src signaling is independent or downstream of
Ras.
Given the quantitative differences between Sin and Cas, we
next examined whether these proteins utilize the same or different pathways to propagate Src signaling. It has been previously shown that
the small GTP-binding protein Ras mediates signaling by constitutive active and oncogenic Src alleles (26, 51, 67). Thus, we further evaluated the pathway(s) that is activated as a result of Sin
and Cas binding to Src and examined whether Ras also plays a role in
Sin-Cas-induced Src signaling.
Tyrosine kinase-stimulated cell growth and proliferation in response to
growth factor receptor stimulation induces the activity of the Ras
proto-oncogene and the extracellular signal-regulated kinases ERK1 and
-2 (23, 49, 71, 91). To assess the role of Ras and ERK in
ligand-mediated Src signaling, we used a well-characterized dominant
negative inhibitor of Ras (RasN17) (30) and examined its
effect on Sin-Cas-induced and Src-dependent ERK1,2 activation. For
these experiments we used proteins that were the most active in
inducing transcriptional activation, namely, Sin
C and Cas
UR
C (Fig. 1; Fig. 3A and B, top).
Using an antibody that specifically recognizes the phosphorylated,
active forms of ERK1,2, we found that both Sin
C and Cas
UR
C induced ERK phosphorylation when coexpressed with c-Src (Fig. 4A, top panel). However, the induction of
ERK phosphorylation by Sin
C and Cas
UR
C was not sensitive to
the RasN17 dominant negative inhibitor, suggesting that the activation
of ERK1,2 was downstream or independent of Ras (Fig. 4A, top panel).
This result is in contrast to published observations showing Ras to be
the main upstream positive regulator of ERK (23, 49, 71,
91). In addition, these results differ from published data that
show Ras to act downstream of oncogenic src alleles
(26, 51, 67). Consistent with the published observations, in
our system we found that activation of ERK1,2 by the constitutively
active Src mutant (SrcY527F) was blocked by the RasN17 inhibitor (Fig.
4A, top panel). The effects of Sin and Cas on increased ERK1,2
phosphorylation were specific given that probing the blots with an ERK
antiserum which recognizes both the phosphorylated and
nonphosphorylated forms of the kinases revealed similar levels of the
proteins (Fig. 4A, bottom panel). The effect of Sin
C and
Cas
UR
C on ERK1,2 activation was Src dependent, since coexpression
of the SrcK295R kinase mutant with Sin
C and Cas
UR
C did not
induce ERK phosphorylation (Fig. 4B, top panel). In the same
experiment, expression of the constitutively active SrcY527F mutant
resulted in ERK1,2 activation; ERK1,2 phosphorylation was again blocked
by the RasN17 inhibitor. Equal levels of total ERK were present in all
lanes (Fig. 4B, bottom panel). Our data therefore suggest that the Sin
and Cas proteins activate ERK1,2 independently or downstream of Ras and that this effect is dependent on Src kinase activity.

View larger version (42K):
[in this window]
[in a new window]
|
FIG. 4.
Induction of ERK1,2 phosphorylation and SRE-dependent
transcriptional activation by Cas and Sin are Ras independent. (A) 293 cells were transfected with c-Src and pEBB vector or Sin C or
Cas UR C as shown. Also cells were transfected with SrcY527F alone,
or empty vector used to express this Src mutant (pEVX), in the presence
of the Ras inhibitor (2 µg) or the Zipneo empty vector (2 µg) as
shown. Total cell extracts were normalized for protein content,
resolved by SDS-PAGE, and blotted with anti-phospho-ERK antibody (E-4)
(top panel). The lower panel represents a Western blot probed with
anti-ERK antibody that recognizes both phosphorylated and
unphosphorylated forms of ERK. (B) 293 cells were transfected as above
but in the presence of the Src kinase mutant or SrcY527F as a positive
control and in the presence of RasN17 inhibitor or empty vector.
Western blots of cell extracts were processed as in panel A. (C) Cells
were transfected with c-Src and Sin C or Cas UR C or with
SrcY527F alone, as shown, with increasing concentrations of the RasN17
inhibitor in the presence of the SRE-luciferase reporter. Percent
stimulation is relative to the activation of luciferase in cells
transfected with c-Src and Sin C or Cas UR C, or SrcY527F in the
presence of the Zipneo empty vector (2 µg) used to express the RasN17
inhibitor, each of which was given a value of 100 (dark gray bars).
Actual fold activation in the absence of the RasN17 inhibitor (dark
gray bars) was 32 ± 3.2 for Sin C, 14 ± 2.4 for
Cas UR C, and 79 ± 16 for SrcY527F. The percent stimulation
obtained with c-Src and Sin C or with Cas UR C or SrcY527F in the
presence of the dominant negative inhibitors is the mean ± standard deviation. The data represent the average of at least five
experiments.
|
|
In addition to ERK activation, we also tested the effect of the RasN17
inhibitor on SRE-dependent transcriptional activation. Consistent with
the ERK activation described above, Sin
C and Cas
UR
C-mediated,
Src-dependent SRE activation was not blocked by the Ras inhibitor (Fig.
4C), whereas activation of the SRE-luciferase reporter by the
constitutively active SrcY527F mutant was inhibited in a
concentration-dependent manner (~60% inhibition [Fig. 4C]). Thus,
these data show that activation of ERK and SRE-mediated transcription
as a result of Sin
C and Cas
UR
C binding to c-Src occur through
a mechanism that is Ras independent. In addition, these results suggest
that signaling through Sin-Cas-activated Src and signaling through
constitutively active Src proteins are mediated by different mechanisms.
Sin- and Cas-induced Src signaling is mediated by Crk.
In
vitro studies have previously shown that a phosphorylated tyrosine
within a YDVP consensus sequence (Y motif) exhibits preferential
binding to the c-Crk SH2 domain (78). c-Crk is a Grb2-like
small adapter molecule with no known enzymatic activity, consisting
mainly of modular regions such as SH2 and SH3 domains (31).
Three of the Sin Y motifs and the majority of the Cas Y motifs are of
the YDVP consensus, suggesting a c-Crk SH2 binding specificity (Fig.
1A). Consistent with the in vitro data, Sin and Cas interact with
endogenous c-Crk in a c-Src- and phosphotyrosine-dependent manner
(1, 72).
To determine whether the association of phosphorylated Sin
C and
Cas
UR
C proteins with endogenous c-Crk was functionally significant, we tested whether an SH3 domain mutant of Crk could inhibit Sin-Cas-induced transcriptional activation. This c-Crk mutant
has been previously described and was used to successfully block
activation of ERK1 by oncogenic v-Abl (81). The W170K point
mutation within the SH3 domain of Crk acts by interfering with binding
to downstream proline-rich containing effector molecules such as the
guanine nucleotide exchange factor (GEF) C3G (82). As shown
in Fig. 5A, the Crk mutant effectively
inhibited SRE-dependent transcriptional activation by Sin
C and
Cas
UR
C in a concentration-dependent manner, suggesting that
c-Crk is required for Src signaling mediated by these proteins. The
effects of the Crk inhibitor on Sin-Cas-induced Src signaling were
specific, particularly when lower concentrations of inhibitor DNA were
used. A small inhibition of v-Raf-induced SRE-luciferase activation was
observed at the highest concentration of the inhibitor (2 µg),
suggesting a nonspecific effect possibly due to toxicity (Fig. 5A).
Similar results were obtained using the AP-1 promoter (data not shown).

View larger version (38K):
[in this window]
[in a new window]
|
FIG. 5.
The adapter Crk mediates Sin- and Cas-induced Src
signaling. (A) 293 cells were cotransfected with c-Src (2 µg) and
Sin C or Cas UR C (1 µg of each) or with a v-Raf expression
plasmid (2 µg) in the presence of empty pEBB vector or increasing
concentrations of the CrkK170 inhibitor. Percent stimulation is
relative to the activation of luciferase in cells transfected with
c-Src and Sin C or Cas UR C, or v-Raf in the presence of the pEBB
empty vector (2 µg) used to express the CrkK170 inhibitor, each of
which was given a value of 100 (dark gray bars). Actual fold activation
in the absence of the CrkK170 inhibitor (dark gray bars) was 39 ± 11 for Sin C, 12 ± 2.8 for Cas UR C, and 126 ± 15 for
v-Raf. The percent stimulation obtained with c-Src and Sin C or with
Cas UR C or v-Raf in the presence of the dominant negative
inhibitors is the mean ± standard deviation. The data represent
the average of at least seven experiments. (B) 293 cells were
cotransfected with c-Src and wild-type (WT) or mutant Sin C (1 µg,
as shown) in the presence of the SRE-luciferase reporter construct.
Data from several experiments (n = 5) were averaged,
and values for samples that expressed the mutant Sin proteins were
normalized to the induction of luciferase activity observed with
wild-type Sin C, which was given a value of 100 (actual increase with
wild-type Sin C was 42 ± 4.7-fold). The percent stimulation is
the mean ± standard deviation. (C) Lysates of 293 cells
expressing c-Src and wild-type or tyrosine mutant Sin C were
immunoprecipitated (IP) with anti-Src antibodies (middle and bottom
panels). Immunoprecipitates were blotted and probed with
antiphosphotyrosine antibody pY20 (middle) or anti-Sin antibody
(bottom). Total cell extracts of the same samples were resolved by
SDS-PAGE, and the membranes were blotted with anti-Sin antibody (top
panel). Consensus sequences containing Y148, Y188, and Y253 are shown
at the bottom of panel B. Amino acids important for kinase specificity
are shown in bold.
|
|
The experiments described above suggest that Src signaling is dependent
on the substrates recruited by the conserved Y motifs of Sin and Cas.
To further examine whether Crk recruitment by the YDVP motifs mediates
the signaling effects of Sin, we introduced point mutations in the
three YDVP motifs of Sin
C, at positions Y148, Y188, and Y253. We
concentrated on Sin because it contains fewer YDVP motifs than Cas. We
found that double mutants containing different combinations of
mutagenized tyrosine residues (as shown) or a single mutation on Y253
significantly blocked the ability of Sin
C to activate SRE-dependent
transcription (Fig. 5B). In addition, a mutant containing substitutions
on all three tyrosines (Y148, Y188, and Y253) inhibited about 90% of
Src-induced transcriptional activation (Fig. 5B). Similar results were
also obtained with the AP-1 reporter construct (data not shown).
The ability of the triple mutant to block transcription correlated with
reduced phosphorylation of this protein by Src (Fig. 5C, middle panel,
lane 6). This was despite the fact that the mutant was expressed to
levels similar to those observed with wild-type Sin
C (Fig. 5C, upper
panel, lane 6) and associated with Src, albeit to a lesser extent than
Sin
C (Fig. 5C, lower panel, lane 6). These results show that
mutations within virtually identical motifs of Sin
C can behave
differently in terms of mediating the effects of Src. These differences
may be due to amino acids N terminal to the tyrosine that are involved
in determining kinase specificity. Indeed, in vitro studies have shown
that the presence of acidic amino acids (D or E) at positions
4 and
3 N terminal to an unphosphorylated tyrosine residue correlates with
Src-kinase specificity (77) (Fig. 5C, bottom). Taken
together, these data suggest that Crk recruitment by the YDVP motifs of
Sin is important for Sin-mediated Src signaling.
The Rap1 GTPase is involved in Cas- and Sin-induced Src
signaling.
It has been recently shown that the SH3 domain of c-Crk
interacts with proline-rich sequences found on C3G (34, 46,
82), a protein that promotes nucleotide exchange on the small
GTP-binding protein Rap1 (38). In our system, we also found
a Src-dependent association of endogenous Crk and C3G with
phosphorylated Sin
C and Cas
UR
C (Fig.
6A). These interactions were dependent on
the kinase activity of Src since the association of Sin and Cas with Crk and C3G was abolished in the presence of the Src kinase mutant (data not shown).

View larger version (39K):
[in this window]
[in a new window]
|
FIG. 6.
Sin- and Cas-induced Src signaling is mediated by the
Rap1 GTPase. (A) 293 cell lysates expressing c-Src and Sin C or
Cas UR C were immunoprecipitated with Crk-specific (left) or
C3G-specific (right) antibodies. Immunoprecipitates (IP) were blotted
and probed with antibody pY20. Membranes were then stripped and blotted
with anti-Crk (bottom left) or anti-C3G (bottom right) antibodies. (B)
293 cells were transfected as in Fig. 5A along with increasing
concentrations of the RapN17 inhibitor as shown. Percent stimulation is
relative to the activation of luciferase in cells transfected with
c-Src and Sin C or Cas UR C, or v-Raf in the presence of the
pcDNA empty vector (4 µg) used to express the Rap1N17 inhibitor, each
of which was given a value of 100 (dark gray bars). Actual fold
activation in the absence of the RapN17 inhibitor (black bars) was
26 ± 6.5 for Sin C, 10 ± 3.3 for Cas UR C, and
86 ± 5.2 for v-Raf. The percent stimulation obtained with c-Src
and Sin C or with Cas UR C or v-Raf in the presence of the
dominant negative inhibitors is the mean ± standard deviation.
The data represent the average of at least six experiments. (C) 293 cell extracts expressing c-Src and vector backbone, Sin C, or
Cas UR C were incubated with GST-RalGDS-RBD or GST-Raf-RBD; the
protein complexes were harvested, separated by SDS-PAGE, and
transferred onto nitrocellulose membranes. The membranes were blotted
with Rap1-specific (top) or Ras-specific (bottom) antibodies. Protein
bands were visualized using ECL. (D) Total extracts from untransfected
or cells expressing pcDNA vector, constitutively active RapV12, or
wild-type Rap (RapWT) were blotted with anti-phospho-ERK (top) or
anti-ERK (bottom). Protein bands were visualized using ECL.
|
|
To address whether Rap1 was a downstream effector for Crk in our
system, we used a dominant negative mutant of Rap1 that is analogous to
the RasN17 inhibitor and blocks activation of the endogenous Rap1
protein (86). We found that, like the Crk inhibitor, Rap1N17
blocked Sin
C- and Cas
UR
C-induced transcriptional activation through the SRE-luciferase reporter, in a concentration-dependent manner (Fig. 6B). In the same experiments, SRE activation by v-Raf was
largely unaffected, particularly at lower concentrations of the
inhibitor, suggesting that the effect of the Rap1 inhibitor is specific
(Fig. 6B). Therefore, these results demonstrate that Rap1 acts
downstream of phosphorylated Sin
C and Cas
UR
C to mediate Src signaling.
To further examine the involvement of Rap1 in Sin- and Cas-mediated Src
signaling, we tested whether Src and Sin
C or Cas
UR
C coexpression resulted in increased levels of active, GTP-bound Rap1.
For this purpose we used a recently developed technique that involves
the use of the GST-RalGDS-RBD fusion protein in affinity binding
assays. This molecule contains a fragment of the Rap1 effector RalGDS,
which specifically binds to the effector-binding domain of activated,
GTP-bound Rap1 (32, 90). We found that coexpression of
Sin
C or Cas
UR
C with c-Src resulted in increased levels of
active, GTP-bound Rap1 (Fig. 6C, upper panel). In the same experiment,
we tested whether Ras was activated as a result of Sin-Cas-mediated
activation of Src. To this end, we used GST fused to c-Raf-RBD, which
contains a fragment of the Ras-binding domain of c-Raf, which is one of
the downstream effector molecules for Ras (21). c-Raf-RBD
specifically recognizes active GTP-bound Ras but not Rap1. We found
that, in contrast to Rap1, coexpression of c-Src with Sin
C or
Cas
UR
C did not induce Ras activation (Fig. 6C, bottom panel).
This data are consistent with results for the dominant negative Ras and
Rap inhibitors and further support the model that Sin- and Cas-induced
activation of Src signaling is mediated exclusively by Rap1. These data
further indicate that different signaling mechanisms are utilized by
ligand-activated versus constitutively active Src.
Rap1 was originally discovered as a transformation suppressor of Ki-Ras
(43), and it has been shown to antagonize Ras function in
different cell systems (9, 10). However, in other cell types
Rap1 has also been shown to have positive effects, i.e., induce
proliferation and growth in Swiss 3T3 cells (29, 96), activate intermediates of the mitogen-activated protein (MAP) kinase
cascade in PC12 cells (86, 95), and mediate bombesin-induced phosphorylation of ERK (66). These observations are
consistent with our results showing that Rap1 and ERK are activated in
response to ligand-induced activation of Src. To show that ERK can be
directly activated in our system, we expressed a constitutively active form of Rap1, Rap1V12, or wild-type Rap1 in 293 cells and assayed for
increases in ERK1,2 phosphorylation. We found that expression of either
RapV12 or wild-type Rap1 leads to increased ERK phosphorylation (Fig.
6D, upper panel), while equal levels of total ERK were observed in all
lanes (Fig. 6D, lower panel). Thus, these data suggest that
overexpressed Rap1 can indeed activate ERK in 293 cells.
We next examined the effect of the different inhibitors on
ligand-induced JNK/stress-activated protein kinase
(SAPK)-mediated, AP-1-dependent gene expression. We found that, as with
the SRE promoter, AP-1-dependent transcriptional activation by Sin
C
and Cas
UR
C was Ras independent and was instead mediated by Crk
and Rap1 (data not shown). However, we were unable to detect direct activation of the JNK/SAPK protein using either an antibody against the
phosphorylated form of this kinase or in vitro phosphorylation of
GST-c-Jun (data not shown). In addition, dominant negative inhibitors
of intermediates of the JNK pathway such as JNKK1 and JNK had no effect
on AP-1-mediated gene expression. However, a dominant inhibitor of
MEK-1 blocked both SRE- and AP-1-mediated transcriptional activation by
all three ligands (data not shown). Thus, it appears that activation of
gene expression through the AP-1 site is not through independent
activation of the JNK pathway but rather the result of ERK-mediated
gene expression.
Signaling through the constitutively active SrcY527F mutant
is mediated by both Ras and Rap1.
The lack of an inhibitory effect
with the Ras inhibitor on Sin and Cas induced activation of c-Src is
surprising in that SRE-mediated transcription in response to tyrosine
kinase activation is predominantly the result of Ras-mediated
activation of the ERK1,2 MAP kinases (23, 49, 71, 91). It
has also been shown that transcriptional activation induced by
constitutively active and oncogenic forms of Src is Ras dependent
(45, 63, 67). Consistent with these observations, we found
that the Ras inhibitor blocked SrcY527F-induced SRE activation
(Fig. 4C). We next examined whether the SrcY527F constitutively active
mutant could activate the Crk-Rap1 signaling pathway, using dominant
negative inhibitors and assaying for Rap activation. We found that both
the CrkK170 and RapN17 mutants inhibited SrcY527F-induced
transcriptional activation of the SRE promoter in a
concentration-dependent manner (Fig. 7A),
suggesting that both the Ras and Rap1 signaling cascades are utilized
by oncogenic Src. Consistent with this result, cotransfection of SrcY527F with both RasN17 and RapN17 resulted in maximal inhibition of
transcription even at the lowest concentrations of Rap and Ras
inhibitor DNA (0.25 µg of each [Fig. 7A]). In addition, in contrast
to Sin and Cas, which preferentially activated Rap1 but not Ras, we
found that expression of the SrcY527F mutant resulted in increased
GTP-bound levels of both Ras and Rap1 (Fig. 7B). Furthermore, as with
the RasN17 inhibitor (Fig. 4A), we found that SrcY527F-mediated
activation of ERK1,2 phosphorylation was also sensitive to the RapN17
inhibitor, whereas v-Raf-induced ERK phosphorylation was unaffected
under the same conditions (Fig. 7C). Thus, these data suggest that the
oncogenic SrcY527F mutant utilizes at least two separate cascades to
ERK phosphorylation and SRE promoter activation, whereas signaling
through ligand-activated Src is more directed and is primarily mediated
by Rap1.

View larger version (45K):
[in this window]
[in a new window]
|
FIG. 7.
Signaling through the constitutively active SrcY527F
mutant is mediated by both Ras and Rap. (A) 293 cells were transfected
with SrcY527F in the presence of the Ras, Crk, and Rap inhibitors and
in the presence of the SRE-luciferase reporter. Percent stimulation
represents the average data from four experiments and was determined
from samples expressing SrcY527F in the presence of empty vectors
(pZipneo, pEBB, and pcDNA) that were used to express the inhibitors
(dark gray bars). Actual activation was 79 ± 16-fold in the
presence of Zipneo, 130 ± 28-fold for pEBB, and 40 ± 6.7-fold for pCDNA. The difference in the SrcY527F fold activation
observed in the presence of the different vectors is likely due to
promoter competition of the transfected plasmids. Luciferase activation
in the presence of the different inhibitors is expressed as a
percentage of the dark gray bar controls ± standard deviation.
(B) Cell extracts expressing the pEVX vector or SrcY527F were incubated
with GST-RalGD-RBD or GST-Raf-RBD; protein complexes were separated,
transferred to membranes, and blotted with Rap- or Ras-specific
antibodies, respectively. Protein bands were visualized using ECL. (C)
293 cell extracts expressing SrcY527F or v-Raf were assayed for ERK1,2
activation in the presence of the RapN17 inhibitor. SrcY527F or v-Raf
(2 µg of each) and RapN17 (4 µg) expression plasmids were used.
Cell lysates were analyzed as described for Fig. 4, using phospho-ERK-
and ERK-specific antibodies.
|
|
 |
DISCUSSION |
Cas and Sin mediate Src-dependent transcriptional activation
through the ERK MAP kinase.
The Src-SH3 domain is important for
c-Src regulation and signaling, and this domain is thought to
participate in signaling specificity by determining the substrate
selectivity of the enzyme (28). In this study we used the
natural c-Src ligands Sin and Cas to activate Src and examine the
mechanisms that mediate signaling under these conditions. In the
experiments described above, we found that phosphorylated Sin and Cas
act downstream of Src to activate transcription through an
SRE-containing promoter. SRE-dependent transcriptional activation has
been shown to depend on activation of Ras and the ERK1,2 MAP kinases.
In our system, activation of transcription through the SRE was Ras
independent and was instead mediated by the related protein Rap1. Our
results for the first time implicate Rap1 in Src kinase signaling and
show that this G protein acts downstream of phosphorylated Sin and Cas
to activate ERK and SRE-dependent transcription.
Cas has been the focus of many studies, which show this protein to
mediate a variety of cellular processes. Recent evidence suggests that
extracellular signals, such as integrin engagement, lead to the
formation of an active Cas-Crk signaling complex, which regulates cell
migration and survival (17, 41), cell cycle progression
(60), and transcriptional activation (24, 35).
These responses are mediated by the ERK and JNK MAP kinase cascades,
which are activated by distinct, upstream-acting signaling complexes.
Thus, activation of the ERK1,2 kinases in response to extracellular
stimuli is mediated by the Crb2-Sos or the Shc-Grb-2-Sos signaling
modules, whereas activation of the JNK MAP kinase is mediated by the
formation of an active Cas-Crk complex (17, 60, 97). In the
integrin receptor system, Cas-Crk coupling is facilitated by
upstream-acting Src and FAK, and this coupling results in the
activation of the small GTP-binding protein Rac. Activation of Rac, in
turn, regulates JNK activation and cell invasion and adhesion
(17). In our system, coupling of Cas and Sin with Crk as a
result of Src-mediated phosphorylation of Cas and Sin induced ERK but
not JNK activation. In addition, a dominant negative mutant of Rac was
not able to block Cas-Sin-induced SRE- or AP-1-dependent
transcriptional activation (unpublished observations).
The lack of an effect of Src-mediated phosphorylation of Sin-Cas and
Crk coupling on JNK activation was unexpected given existing evidence
suggesting that Src-induced Cas phosphorylation in response to integrin
stimulation mediates integrin-dependent JNK activation (8, 60, 74,
87). However, to our knowledge there is no evidence that directly
links Src-mediated Cas phosphorylation to JNK activation. On the other
hand, consistent with our results showing that Cas and Sin are not
involved in Src-dependent JNK activation is evidence suggesting that a
dominant negative inhibitor of Cas does not inhibit v-Src-induced JNK
activation (24). It is possible therefore, that other
kinases act downstream of Src to phosphorylate Cas and activate JNK in
response to integrin stimulation. Indeed, it has been shown that
although Cas phosphorylation is abolished in Src
/
cells, expression of a truncated, kinase-deficient Src protein in the
same cells restores Cas phosphorylation and promotes Cas and FAK
association and FAK-mediated phosphorylation of Cas (74). These observations suggest that there are differences in the formation of signaling complexes in the case of activated Src (either oncogenic or ligand induced) and activated integrin receptors that may result in
different signaling mechanisms through these proteins. Thus, additional
elements may be recruited downstream of activated integrin receptors
versus activated Src to induce JNK activation.
In contrast to the inability of the Cas and Sin proteins to activate
JNK, we found that the ERK1,2 kinases were efficiently activated by
these proteins in a Src-dependent manner (Fig. 4A and B). Although it
has been suggested that Src-mediated phosphorylation of Cas may mediate
ERK2 activation (74), the majority of existing evidence
shows that Cas-Crk coupling in response to extracellular stimuli
functions upstream of JNK (17, 60, 97). In addition, integrin- and cytokine-induced activation of ERK1,2 is mediated predominantly by the Grb2-Sos complex, and dominant negative Cas or Crk
mutants do not block ERK activation (8). Furthermore, Src
has been shown to mediate ERK activation in response to integrin stimulation either by promoting binding of Grb2-Sos to FAK or Pyk2 or
by promoting formation of the Shc-Grb2-Sos complex (8). It
has been previously suggested that Src may activate ERK through FAK-mediated phosphorylation of Cas in response to fibronectin, in the
absence of Grb2 binding to FAK (74). Our experiments revealed that a dominant negative mutant of Ras had no effect on Sin-
and Cas-mediated ERK phosphorylation and induction of transcription,
whereas a dominant negative Crk mutant inhibited SRE-dependent
transcriptional activation (Fig. 5), as well as ERK activation (data
not shown). In the same experiments we also found that constitutively
active Src can activate ERK through two distinct pathways: one that
utilizes the Grb2-Sos-Ras cascade and another that involves the
Crk-C3G-Rap1 signaling complex (Fig. 4 and 7C). Thus, it is possible
that under different stimulating conditions these pathways either
independently or in concert mediate ERK activation and need not be
mutually exclusive. The experiments presented here show that the
Cas-Sin-Crk-Rap1 pathway can indeed activate the ERK cascade and
mediate signaling downstream of activated Src.
Src SH3-binding proteins differentially activate c-Src
signaling.
In the experiments described above, we found that
although the different Sin and Cas proteins bound to and were
phosphorylated by Src to similar levels, they elicited quantitatively
different responses as measured by transcriptional activation. Despite
these quantitative differences, both Sin and Cas mediated Src signaling through the activation of the Crk-Rap1-ERK1,2 signaling cascade.
The quantitative differences in transcriptional activation we observe
with the Sin and Cas proteins do not appear to depend on differential
binding affinities of these molecules for the Src SH3 domain. This is
based on the observation that substitution of the Cas proline-rich
motif with that of Sin did not increase the levels of transcriptional
activation by Cas
UR
C (Fig. 3A and B, lanes 7). Alternatively, the
quantitatively different effects of Sin
C and Cas
UR
C on
transcription could be due to the tyrosine-containing motifs of these
proteins. This hypothesis is supported by the observation that
Sin-dependent transcriptional activation is dependent on specific YDVP
motifs and that these motifs are not functionally equivalent (Fig. 5B).
For example, Y188 and Y253 seem to have the strongest effect on the
ability of Sin to mediate Src signaling (Fig. 5B). This correlates with
the presence of amino acid positions
4 to
1 N terminal to Y188 and
Y253 that contain the acidic amino acids D and E, which have been shown
to be important for Src kinase specificity (Fig. 5C) (77).
Moreover, the sequence upstream of Y253 (DEGI) is identical to the
sequence described as optimal for Src kinase recognition by Songyang et
al. (77) (Fig. 5C). In contrast, amino acids upstream of
Y148 contain only one E residue (Fig. 5C), and a mutation on Y148 has
no effect on transcriptional activation (Fig. 5B).
Although Cas contains more YDVP motifs than Sin, it was not as
efficient as Sin in promoting Src signaling. This could be due to
phosphorylation of a small subset of these motifs by Src, given that
only three of the seven YDVP motifs of Cas contain D and E residues
upstream of the tyrosine. Thus, the quantitative differences in
transcriptional activation levels that we observe between Sin and Cas
could be due to more efficient phosphorylation of some Sin motifs
versus those of Cas. This, in turn, could result in more effective
activation of downstream signaling intermediates. In support of this
model, we observed that the mechanism of signaling (in terms of
transcriptional activation) is the same for both Sin and Cas and is
mediated by Rap1. However, it is also possible that Crk binding to the
phosphorylated YDVP motifs of Sin may recruit other kinases that can
then phosphorylate the unique Y motifs of Sin, thus contributing to the
stronger effects of Sin on transcription. In future experiments, the
use of the YDVP mutants in conjunction with additional mutations on
other motifs will address these questions and may identify other
individual elements that are important for Sin-mediated transcription.
c-Src signaling in response to ligand binding is mediated by Crk
and Rap1, functioning upstream of ERK.
The experiments presented
above show that Cas and Sin can effectively activate the Crk-Rap1
signaling complex upstream of ERK and the SRE promoter and that this
activation requires the binding of Crk to the phosphorylated YDVP
motifs of Sin and Cas. Crk has been shown to bind to C3G through a Crk
SH3 and C3G proline-rich motif interaction (82). Formation
of the Crk-C3G complex in turn leads to Rap1 activation
(34). In our experiments we found that both endogenous Crk
and C3G associated with phosphorylated Sin and Cas proteins (Fig. 6A).
These results suggest that phosphorylated Cas-Sin-induced activation of
Rap1 is mediated by the Crk-C3G complex. It has been shown recently
that Rap1 activation is mediated by different signaling pathways,
involving second messengers such as calcium, diacylglycerol, and cyclic
AMP (cAMP) (3, 32, 98). The formation of active, GTP-bound
Rap1 is regulated by three different families of GEFs consisting of
C3G, which regulates tyrosine kinase-induced Rap1 activation through
Crk and Cbl (39, 69, 76), the guanine nucleotide-releasing
proteins, which contain calcium and diacylglycerol motifs
(25), and the Epac family of proteins, which are regulated
by cAMP (22, 41). More recently, another protein family, the
PDZ-GEFs, was characterized, members of which exhibit nucleotide
exchange activity specific for Rap1 and -2 (41). Thus, we
cannot exclude the possibility that other, newly discovered
Rap1-specific GEFs are involved in Rap1 activation in our system. The
involvement of different GEFs in Rap1 activation will be explored in
future experiments.
Rap1 was originally identified as the product of a cDNA (Krev-1)
capable of suppressing transformation by Ki-Ras (43). More recently, both positive and negative functional outcomes have been
described for activated Rap1 (see reference 6 for
review). Thus, in addition to the transformation-suppressing effects of Rap1 (42, 43, 65), introduction of the active GTP-bound form
of Rap1 into fibroblasts inhibits Ras-mediated activation of MAP kinase
(19). Moreover, cAMP-dependent activation of Rap1 correlates
with down-regulation of the MAPK-ERK pathway (27, 29, 70).
On the other hand, other studies in different cell types indicate that
Rap1 has additional functions besides being an antagonist of Ras
signaling (9). Recently, Rap1 was shown to act
synergistically with Ras in mediating nerve growth factor-induced differentiation of the phaeochromocytoma cell line PC12 (95) and to mediate ERK phosphorylation in response to cAMP (86). In addition, the activity of Rap1 has been shown to increase upon treatment of NIH 3T3 cells with the neuropeptide growth factor bombesin, and increased Rap1 activity correlates with increased phosphorylation of the MAP kinase ERK and increased proliferation (9, 66). Furthermore, Rap1 has been shown to induce DNA
synthesis and oncogenic transformation in Swiss 3T3 cells (4,
96).
Rap1 is ~50% homologous to Ras, and the two proteins have effector
domains that exhibit striking similarity (10). The high degree of homology of the Ras and Rap1 effector domains suggested that
these proteins bind to the same effector molecules. Consistent with
this model, Rap1 has been shown to interact with the Ras effector Raf1,
although this interaction does not appear to lead to activation of this
protein. Based on these data, it has been proposed that Rap1 may
antagonize the function of Ras by competing for downstream effector
molecules (19, 85). However, recent evidence suggests that
growth factors that activate the Ras/Raf pathway also activate Rap1 and
that this activation does not interfere with growth factor receptor
signaling (98). In addition, increasing the levels of
GTP-bound Rap1 by tetradecanoyl phorbol acetate does not inhibit ERK
activation by platelet-derived growth factor and epidermal growth
factor (98). In our system, activation of Rap1 correlates
with ERK activation and increased gene expression. Furthermore, in the
case of the SrcY527 mutant, Rap1 appears to act in concert with Ras to
promote Src signaling. Taken together, these observations suggest that
Rap1 function in cellular pathways may be more complex than previously
thought and that its effect on cellular processes may be determined by
cellular context.
Ligand-activated versus oncogenic Src signaling.
In the
experiments described above, we show that truncated Sin and Cas
proteins mediate c-Src signaling through the Rap1 GTPase. These observations are important because (i) our results for the first
time implicate a GTPase other than Ras in Src signaling, (ii) ERK
activation can be mediated by small GTP proteins other than Ras, and
(iii) the mode of Src activation (oncogenic versus ligand induced) may
determine the signaling pathways activated by Src. The latter
observation is particularly interesting given the fact that studies
using constitutively active and oncogenic forms of Src have shown Src
to act upstream of Ras (26, 51, 67). Consistent with this,
our results show that signaling through the transforming allele
SrcY527F is also Ras as well as Rap1 dependent (Fig. 7). In addition, a
recent report by Hakak and Martin (35) showed that Cas
mediates transcriptional activation of the Egr-1 SRE by v-Src and that
this activation was through Grb2 and the Ras-MEK-ERK pathway. However,
the increase in transcriptional activation was not dependent on the
substrate region of Cas that contains the YXXP motifs, since deletion
of this region resulted in levels of luciferase activity equivalent to
that induced by full-length Cas. Consistent with this observation, a
Crk-II SH3 mutant had no effect on luciferase activity, suggesting that
the effect of Cas on v-Src-dependent transcriptional activation is mediated by a Ras-dependent mechanism which is different from the one
we are describing.
These observations support our model that the signaling mechanisms
through activated forms of Src are more complex than the mechanisms
that mediate ligand-induced Src signaling (Fig.
8). The differences that we observe in
ligand-induced Src signaling versus signaling through constitutively
active Src proteins could be due to signaling constraints imposed by
the activating ligands through the recruitment of defined,
downstream-acting sets of substrates. This stands in contrast to the
broader spectrum of responses elicited by deregulated Src kinase
activity and interactions between cellular substrates and transforming
Src proteins. For example, v-Src as well as the Y527F Src proteins
contain mutations that result in the disruption of intramolecular
inhibitory interactions between the regulatory and kinase domains of
Src (34, 45). This release of intramolecular inhibition
abolishes the requirement for specific, high-affinity interactions of
SrcY527F with putative substrates, resulting in a wider spectrum of
cellular proteins interacting with and becoming phosphorylated by this
mutant. As a result, multiple signaling pathways are activated. Indeed
we found this to be the case in our system expressing the constitutive active SrcY527F in that this mutant activates at least two separate signaling cascades (Fig. 8).

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 8.
Model for ligand-induced c-Src-dependent signal
transduction leading to MAP kinase and transcriptional activation.
Binding of the proline-rich motifs of Sin and Cas to the Src SH3 domain
activates the c-Src tyrosine kinase activity, and the proteins become
phosphorylated on tyrosine residues. Src-mediated phosphorylation of
Sin and Cas results in the recruitment of the Crk-GEF signaling
complex, which in turn activates Rap1 and ERK and induces SRE-mediated
gene expression. On the other hand, mutations that disrupt the
intramolecular interactions of Src, such as a point mutation on the
C-terminal tyrosine 527, result in an open conformation of the enzyme,
which then interacts nonspecifically with multiple cellular substrates.
This, in turn, leads to the activation of at least two signaling
cascades mediated by the Ras and Rap GTPases.
|
|
In contrast to oncogenic alleles, activation of c-Src under physiologic
conditions involves directed engagement of the conserved domains of
c-Src by their ligands. For example, in response to growth factor
binding, growth factor receptors activate Src by providing
high-affinity ligands for the Src SH2 domain in the form of
phosphotyrosines (83). This mechanism of activation excludes
nonspecific binding of other proteins and ensures activation of
specific signaling pathways for each receptor type. The use of Src SH3
ligands to activate c-Src more closely resembles the in vivo
conditions, in that these ligands provide high-affinity binding sites
for the Src SH3 domain. Once bound to Src, these ligands induce Src
activation and subsequently serve as Src substrates and effector
molecules. Given that each phosphorylated adapter molecule can attract
a defined set of cytoplasmic intermediates, Src signaling through the
recruitment of natural Src SH3 ligands may be more specific than
signaling through constitutively active forms of Src. Whether
coexpression of Src SH3 ligands and active Src alleles affects the
signaling and transforming properties of oncogenic Src proteins remains
to be determined.
 |
ACKNOWLEDGMENTS |
The work was initiated in the laboratory of David Baltimore, and
we thank him for support. We thank C. Roman and A. Koleske for
critically reading the manuscript. We also thank C. Hauser for the AP-1
construct and P. Stork for the Rap1N17 mutant.
This work was supported in part by American Cancer Society grant
RPG99-09-01MGO and by Department of Defense grant BC980976. L.X. is
supported by American Cancer Society grant RPG99-09-01MGO. K.A.
was supported in part by Department of Defense grant BC980671.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Pharmacology, College of Physicians and Surgeons of Columbia
University, PH 7W Rm. 318, 630 West 168th St., New York, NY 10027. Phone: (212) 305-2705. Fax: (212) 305-8780. E-mail:
ka141{at}columbia.edu.
<